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A B S T R A C T
Purpose
One third of patients with triple-negative breast cancer (TNBC) achieve pathologic complete response (pCR) 
with standard neoadjuvant chemotherapy (NACT). CALGB 40603 (Alliance), a 2  2 factorial, open-label, 
randomized phase II trial, evaluated the impact of adding carboplatin and/or bevacizumab.
Patients and Methods
Patients (N  443) with stage II to III TNBC received paclitaxel 80 mg/m2 once per week (wP) for 12 weeks, 
followed by doxorubicin plus cyclophosphamide once every 2 weeks (ddAC) for four cycles, and were 
randomly assigned to concurrent carboplatin (area under curve 6) once every 3 weeks for four cycles and/or 
bevacizumab 10 mg/kg once every 2 weeks for nine cycles. Effects of adding these agents on pCR breast 
(ypT0/is), pCR breast/axilla (ypT0/isN0), treatment delivery, and toxicities were analyzed.
Results
Patients assigned to either carboplatin or bevacizumab were less likely to complete wP and ddAC without 
skipped doses, dose modification, or early discontinuation resulting from toxicity. Grade  3 neutropenia 
and thrombocytopenia were more common with carboplatin, as were hypertension, infection, thrombo-
embolic events, bleeding, and postoperative complications with bevacizumab. Employing one-sided P 
values, addition of either carboplatin (60% v 44%; P  .0018) or bevacizumab (59% v 48%; P  .0089) 
significantly increased pCR breast, whereas only carboplatin (54% v 41%; P  .0029) significantly raised 
pCR breast/axilla. More-than-additive interactions between the two agents could not be demonstrated.
Conclusion
In stage II to III TNBC, addition of either carboplatin or bevacizumab to NACT increased pCR rates, 
but whether this will improve relapse-free or overall survival is unknown. Given results from 
recently reported adjuvant trials, further investigation of bevacizumab in this setting is unlikely, but 
the role of carboplatin could be evaluated in definitive studies, ideally limited to biologically defined 
patient subsets most likely to benefit from this agent.
J Clin Oncol 33:13-21. 
INTRODUCTION
Triple-negative breast cancer (TNBC), character-
ized by absent or minimal expression of estrogen
(ER)andprogesterone receptors (PgRs) andhuman
epidermal growth factor receptor 2 (HER2), ac-
counts for 15% to 20% of invasive breast cancers
diagnosed in the United States. It is more common
in younger women, African Americans, Hispanics,
and BRCA1-mutation carriers. With no targetable
characteristic molecular abnormalities yet identi-
fied, standard treatment for TNBC remains chemo-
therapy. Inearly-stageTNBC, recurrence-free (RFS)
and overall survival (OS) are improved significantly
with adjuvant chemotherapy, including dose-dense
treatment,1 butoverall prognosis remains inferior to
that of other breast cancer subtypes, with higher risk
of early relapse, often involving viscera or the CNS.
Approximately one third of patients with stage
II to III TNBC treated with anthracycline- and
taxane-based neoadjuvant chemotherapy (NACT)
achieveapathologic complete response (pCR).As in
other aggressive cancers, pCR is associated with improved outcomes,
whereas patients with residual disease have an increased risk of recur-
rence.2,3
Platinum analogs attack cancer cells by inducing double-
stranded DNA breaks. As single agents, they have limited efficacy in
heavily pretreated metastatic breast cancer,4 but greater activity has
been seen inBRCA-mutation carriers, with pCR rates 70% in small
neoadjuvant trials.5,6 BRCA-mutated and sporadic TNBC have simi-
lar biologic characteristics and mRNA gene expression patterns,
motivating further study of platinums in this subtype.7 Although
single-agent cisplatin yielded fewpCRs in sporadicTNBC,8 pilot stud-
ies of the addition of cisplatin or carboplatin to standard NACT have
reported rates as high as 75%.9,10
Bevacizumab binds and inactivates vascular endothelial growth
factor 1, believed to support the growth and maintenance of tumor
neovasculature necessary for survival and metastasis. In metastatic
TNBC, addition of bevacizumab to once-per-week paclitaxel im-
proves response rates and time to progression.11,12Whether the addi-
tionof bevacizumab toNACT inTNBCcould improvepCR rates and
long-term outcomes was unknown.
The CALGB (Cancer and Leukemia Group B) 40603 trial was
designed to examine the impact of adding carboplatin and/or bevaci-
zumab to conventionalNACT inTNBCon clinical activity,measured
by pCR rates, and toxicity. Correlative studies to identify markers of
response and resistance, including intrinsic subtype (basal-like v oth-
ers), will be reported separately.
PATIENTS AND METHODS
Patient Population
Eligible patients had operable, biopsy-confirmed, previously un-
treated, clinical stage II to III noninflammatory invasive breast cancer, with
ER and PgR expression 10% and HER2 negativity, defined by immuno-
histochemical (IHC) staining 0 to 1 or fluorescence in situ hybridization
ratio 2.0 if IHC 2 or IHCnot performed. Adequate hematologic, renal,
and hepatic function, normal cardiac function by echocardiogram or
radionuclide ventriculogram, and a negative pregnancy test in women of
childbearing potential were required. Patients were excluded for grade 2
neuropathy or contraindications to treatment with bevacizumab, includ-
ing uncontrolled hypertension.
Study Procedures
Magnetic resonance imaging was preferred for baseline breast imaging.
In patients with clinical stage III disease, imaging studies to rule out overt
metastatic disease were recommended. Surgeons were asked to assess patient
eligibility for breast-conserving surgery (BCS) before treatment. In patients
with clinicallypositive axillae, histologic confirmationbybiopsyorfine-needle
aspiration was encouraged. Patients with clinically negative axillae could un-
dergo pretreatment sentinel lymphnode (SLN) sampling. Tumor biopsies for
correlative studies—two fixed cores in RNAlater and formalin and, where
feasible, two frozen cores in optimal cutting temperature compound—
were required.
Figure 1 illustrates the treatment schema. All patients received paclitaxel
80mg/m2onceperweek(wP) for12weeks followedbydoxorubicin60mg/m2
and cyclophosphamide 600 mg/m2 once every 2 weeks with myeloid growth
factor support (ddAC) for four cycles. Theywere randomly assigned to receive
wPwith orwithout concurrent carboplatin at an area-under-the curve (AUC)
dose of 6 once every 3 weeks for four cycles and independently to treatment
with or without bevacizumab 10 mg/kg once every 2 weeks for nine cycles
during administration of wP and the first three cycles of ddAC. Patients were
examined every 2 to 3 weeks; patients experiencing progression during wP
administration were switched to ddAC, whereas progression while receiving
ddAC resulted in early surgery.
wP was skipped for an absolute neutrophil count (ANC) 800/L or
platelet count 50,000/L and permanently reduced by 10 mg/m2 if treat-
ment was held 2 consecutive weeks for neutropenia, if ANCwas 100/L at
any time, or if febrile neutropenia or grade 2 peripheral neuropathy occurred.
Carboplatin was delayed for platelet count  75,000/L and permanently
reducedby25%after a2-weekdelay for thrombocytopeniaorplatelet count
25,000/L at any time. Bevacizumab dose was never reduced, but treatment
washeld forANC500/L,platelet count50,000/L,uncontrolledhyper-
tension, or any grade 3 toxicity attributed to this agent. ddACwas delayed for
ANC 1,000/L or platelet count 75,000/L, and both agents were dose
reduced for treatment delay 1 week or febrile neutropenia.
After completing NACT, patients underwent repeat cardiac evaluation
and reassessment of eligibility for BCS, followed by surgery, 4 to 8 weeks after
cycle four of ddAC, thus at least 6 weeks after the last dose of bevacizumab.
Axillary samplingwas required except in patientswithnegative SLNspretreat-
ment,but extentof surgeryandsubsequent irradiationweredeterminedby the
treating physicians. Core biopsies of residual tumorwere obtained in consent-
ing patients. Patients weremonitored for immediate and delayed postsurgical
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Fig 1. Schema of randomized phase II
CALGB (Cancer and Leukemia Group B)
40603 trial. ddAC, dose-dense doxorubicin
plus cyclophosphamide. (*) Researchbiopsies
if residual tumor. (†) Physician discretion.
complications. No postoperative adjuvant therapy was planned, but addi-
tional systemic therapy was not prohibited.
Pathologic Evaluation
Pathologic response was determined locally, without central pathologic
review. pCRbreast was defined as the absence of residual invasive diseasewith
orwithoutductal carcinoma in situ (ypT0/is). pCRbreast/axillawasdefinedas
pCR breast and the absence of any tumor deposit  0.2 mm in sampled
axillary nodes (ypT0/isN0). Patients with pCR breast and negative pretreat-
ment SLNs were considered to have achieved pCR breast/axilla. For non-
pCRs, pathologists were asked to record residual cancer burden (RCB).13
Data Collection and Analysis
CALGB 40603 was a randomized, open-label phase II study. After strat-
ification by baseline clinical stage (II v III), patients had an equal probability of
assignment to any of the four treatment arms. A modified intent-to-treat
approach that includedall patientswhobegan treatmentwasused for analyses.
Patients who withdrew consent for subsequent data submission before com-
pletingNACTwereexcluded frompCRanalyses,whereas thosewhoremained
in the study but did not undergo surgery were considered to be non- pCRs.
The study used a 2 2 factorial design. Statistical power was based on
two separate and independent pairwise comparisons—one for each factor
(carboplatin and bevacizumab)—of pCR breast between the control and
experimental groups using a 1-df 2 test. 95% CIs around pCR rates were
calculated using binomial methods. To evaluate interactions between factors
and clinical stage, corresponding terms were included in logistic regression
models; however, because the study was not powered to test interactions,
resulting P values were considered descriptive and not formal assessments
of significance.
The overall study was designed to detect increases in the pCR breast rate
from 35% in the control group to 55% for either carboplatin or bevacizumab
(one-sided  of 0.05). To test these hypotheses in the subpopulation of basal-
like tumors (defined by gene expression analysis) with 90% power, 210 such
patientswere required.To achieve this goal, study accrualwas increased to 445
patients, resulting in95%power in theoverall studypopulation.All analyses
were conductedbyCALGB(Alliance) statisticiansusingSAS software (version
9.2; Cary, NC).
Secondary end points included pCR breast/axilla, treatment delivery,
treatment-related toxicities (as defined by Common Toxicity Criteria for Ad-
verse Events, version 4.0), RCB, conversion from clinically node-positive to
pathologically node-negative status, and conversion from BCS-ineligible to
BCS-eligible status after treatment. Patients will be monitored for RFS, time
to first failure, and OS for 10 years.
Study data were collected and data quality monitored by the CALGB
(Alliance) Statistics and Data Center and the study chair according to group
policiesandstored in theCALGB(Alliance)database.Thecutoff for this report
was October 2013.
The protocol was approved by the central institutional review board of
the National Cancer Institute and institutional review boards at participating
sites. All patients provided written informed consent. The National Cancer
Institute Cancer Therapy Evaluation Program, Genentech USA, a division of
F. Hoffman-La Roche, and the Breast Cancer Research Foundation provided
support for this trial and were permitted to review the manuscript before
submission. Additional funding from the American Recovery and Reinvest-
ment Act to the Coalition for Cancer Cooperative Groups supported imple-
mentation of an integrated accrual plan.
RESULTS
Patient Characteristics
BetweenMay 2009 andAugust 2012, 454 patients were enrolled;
11 never started protocol treatment (CONSORT diagram shown in
Fig 2). Characteristics of the 443 treated patients are listed in Table 1.
Most were between ages 40 and 59 years; 72% were white, including
8% Hispanic, and 20% were black. Two thirds had clinical stage II
disease. The majority had T2 tumors; slightly  half were clinically
nodepositive; 76%hadhigh-gradedisease;90%had invasiveductal
carcinomas, whereas few had ER (6%) or PgR (4%) expression 1%
(datanot shown).Baseline characteristicsweregenerallywell balanced
among treatment arms, but a higher percentage of patients judged
Patients enrolled
(N = 454)
2 × 2 random assignment
Arm 1: wP-ddAC
Assigned (n = 115)
  Never began treatment (n = 7)
  Began treatment* (n = 108)
    Withdrew presurgery (n = 1)
    Assessable for pCR† (n = 107)
      Did not undergo surgery (n = 1)
      Underwent surgery (n = 106)
Arm 2: wP-ddAC + Bev
Assigned (n = 113)
  Never began treatment (n = 3)
  Began treatment* (n = 110)
    Withdrew presurgery (n = 5)
    Assessable for pCR† (n = 105)
      Did not undergo surgery (n = 0)
      Underwent surgery (n = 105)
Arm 3: wPCarbo-ddAC
Assigned (n = 113)
  Never began treatment (n = 0)
  Began treatment* (n = 113)
    Withdrew presurgery (n = 2)
    Assessable for pCR† (n = 111)
      Did not undergo surgery (n = 3)
      Underwent surgery (n = 108)
Arm 4: wPCarbo-ddAC + Bev
Assigned (n = 113)
  Never began treatment (n = 1)
  Began treatment* (n = 112)
    Withdrew presurgery (n = 2)
    Assessable for pCR† (n = 110)
      Did not undergo surgery (n = 2)
      Underwent surgery (n = 108)
Started treatment (n = 108)
  Completed (n = 94; 87%)
  Stopped for toxicity (n = 1)
  Stopped for PD (n = 6)
  Refused treatment (n = 2)
  Other (n = 0)
  Unknown (n = 5)
Started treatment (n = 110)
  Completed (n = 83; 75%)
  Stopped for toxicity (n = 12)
  Stopped for PD (n = 1)
  Refused treatment (n = 2)
  Other (n = 6)
  Unknown (n = 6)
Started treatment (n = 113)
  Completed (n = 90; 80%)
  Stopped for toxicity (n = 7)
  Stopped for PD (n = 4)
  Refused treatment (n = 2)
  Other (n = 4)
  Unknown (n = 6)
Started treatment (n = 112)
  Completed (n = 83; 77%)
  Stopped for toxicity (n = 14)
  Stopped for PD (n = 1)
  Refused treatment (n = 8)
  Other (n = 2)
  Unknown (n = 4)
Fig 2. CONSORT diagram. Bev, bevacizumab; Carbo, carboplatin; ddAC, dose-dense doxorubicin plus cyclophosphamide; pCR, pathologic complete response; PD,
progressive disease; wP, paclitaxel once per week.
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Secondary End Points
pCR breast/axilla rates were also higher with the addition of
carboplatin or bevacizumab (Fig 3B). With carboplatin, the percent-
age of patients who achieved pCR breast/axilla increased significantly
from 41% to 54% (OR, 1.71; P .0029), whereas the increase in the
pCRbreast/axilla ratewith bevacizumab (52% v 44%)didnot achieve
statistical significance (OR, 1.36; P  .057). Again, patients who re-
ceivedbothagentshad thehighest pCRrate (60%),withno significant
interaction between their effects (P .43).
pCR rates were higher with carboplatin or bevacizumab in both
clinical stage II and III disease. Exploratory analyses did not demon-
strate a differential effect on pCR for either agent by clinical stage.
Other measures of response, including percentage of patients with
eitherpCRbreast/axillaorminimal residualdisease (RCBclasses0and
I) and conversion from clinically node-positive to pathologically
Table 1. Patient Demographic and Clinical Characteristics
Characteristic
Total
Patients
(N  443)
Arm One: wP 3 ddAC
(n  108; %)
Arm Two: wP 3 ddAC 
Bev (n  110; %)
Arm Three: wPCarbo 3
ddAC (n  113; %)
Arm Four: wPCarbo 3 ddAC 
Bev (n  112; %)No. %
Age, years
 40 103 23 21 28 20 23
40-59 266 60 59 57 57 67
 60 74 17 19 15 23 10
Race
White 320 72 73 74 71 71
Black 89 20 19 19 24 19
Asian 13 3 1 5 4 3
Other/missing 21 5 7 2 1 7
Clinical stage
II 300 68 69 66 68 67
III 143 32 31 34 32 33
Tumor grade
Low 6 1 0 2 2 2
Intermediate 47 11 8 13 10 12
High 336 76 83 72 75 73
Missing 54 12 8 14 13 13
T stage
1 48 11 6 14 11 13
2 288 66 72 60 63 65
3 88 20 19 25 19 17
4 10 2 2 0 4 4
Missing 9 2 2 1 4 1
N stage
0 186 42 45 38 42 42
1 184 42 42 47 41 37
2 34 8 6 7 7 10
3 9 2 3 1 1 4
Missing 30 7 4 6 9 8
BCS Candidate
(n  414) (n  101) (n  103) (n  104) (n  106)
No. % No. % No. % No. % No. %
Yes 236 57 62 61 67 65 57 55 50 47
No 178 43 39 39 36 35 47 45 56 53
Abbreviations: BCS, breast-conserving surgery; Bev, bevacizumab; Carbo, carboplatin; ddAC, dose-dense doxorubicin plus cyclophosphamide; wP, paclitaxel once
per week.
On basis of surgeon’s baseline assessment.
BCS ineligible at baseline were assigned to arms three and four. Of 52 
clinically node-negative patients who underwent pretreatment SLN 
sampling, 14 had at least one positive node.
Clinical Efficacy
The impact of the addition of carboplatin and/or bevacizumab 
on the primary end point (pCR breast) is illustrated in Figure 3A. 
Adding either agent significantly increased the pCR breast rate; 60% of 
patients who received carboplatin achieved pCR breast compared 
with 46% of those who did not (odds ratio [OR], 1.76; P  .0018). 
Patients treated with a bevacizumab-containing regimen had a pCR 
breast rate of 59% compared with 48% of those who were not (OR, 
1.58; P  .0089). Patients assigned to both agents (arm four) had the 
highest pCR breast rate (67%), with no significant interaction between 
their effects (P  .52).
node-negative status, generally followed the same pattern (Table 2).
Of patients judged ineligible for BCS at baseline, more were consid-
ered BCS eligible after treatmentwith either carboplatin (57% v 44%)
or bevacizumab (54% v 49%), although these differences were not
statistically significant.Thepercentageofpatientswhoactuallyunder-
went BCS, by treatment arm, and other surgical end points will be
reported at a later date.
Treatment Delivery and Toxicity
Figure 4 illustrates delivery of wP and ddAC by treatment arm.
Patients assigned to carboplatin weremore likely tomiss two doses
of wP (36% v 16%), but only those assigned to both carboplatin and
bevacizumab (arm four)were substantiallymore likely tomiss ddAC.
Patients assigned to either investigational agent were more likely to
require dose reduction of wP (26% v 12%) or ddAC (22% v 8%)
compared with controls (data not shown). Because of treatment de-
lays and toxicities, only 80% of patients assigned to carboplatin re-
ceived all four planned doses, and only 66% of patients assigned to
bevacizumab received eight of nine planned doses. Patients receiv-
ing the control regimen (arm one) were more likely to complete
NACT per protocol (87%); only one patient ( 1%) discontinued
treatment because of toxicity, and six (6%) did so because of progres-
sive disease (Fig 2). Patients assigned to the experimental arms were
more likely to stop treatment early becauseof toxicity, including seven
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Fig 3. (A) Pathologic complete response (pCR) breast (ypT0/is); (B) pCR breast/axilla (ypT0/is N0); 95% CIs shown in parentheses.
Table 2. Response Data
End Point
No Carbo: Arms
One and Two
(n  212; %)
With Carbo: Arms
Three and Four
(n  221; %)
No Bev:
Arms One
and Three
(n  218; %)
With Bev:
Arms Two
and Four
(n  215; %)
Arm One:
Control
(n  107; %)
Arm Two:
With Bev
(n  105; %)
Arm Three:
With Carbo
(n  111; %)
Arm Four: With
Bev and Carbo
(n  110; %)
Primary
pCR breast 46 60 48 59 42 50 53 67
95% CI, % 40 to 53 54 to 66 41 to 54 52 to 65
OR 1.76 1.58
P .0018 .0089
Clinical stage II 45 60 47 59 42 49 51 70
Clinical stage III 48 60 50 59 42 55 57 62
Secondary
pCR breast/axilla 41 54 44 52 39 43 49 60
95% CI, % 35 to 48 48 to 61 38 to 51 45 to 58
OR 1.71 1.36
P .0029 .0570
Clinical stage II 41 55 44 52 41 42 47 63
Clinical stage III 41 53 44 50 36 45 51 54
Clinical N 3 pN0 65 75 69 71 67 62 70 80
RCB 0  I 56 67 55 68 51 61 59 75
BCS ineligible 3 eligible 44 57 49 54 41 47 55 59
95% CI, % 33 to 55 48 to 66 39 to 59 44 to 64
Abbreviations: BCS, breast-conserving surgery; Bev, bevacizumab; Carbo, carboplatin; OR, odds ratio; pCR, pathologic complete response; RCB, residual
cancer burden.
One sided.
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(6%) for carboplatin only and 26 (12%) for bevacizumab with or
without carboplatin, refusal of further treatment, or unspecified rea-
sons. Fourpatients (3%)assigned to carboplatinonly and two(1%)
assigned tobevacizumab (arms twoand four) stopped treatment early
because of disease progression.
Table 3 lists grade  3 toxicities. Incidence of grade 3 to 4
neutropenia and thrombocytopenia was higher with the addition of
carboplatin; however, incidence of febrile neutropenia, which usually
occurredduring treatmentwithddAC,was significantlyhigheronly in
arm four. Compared with the non–bevacizumab-containing regi-
mens, patients assigned to bevacizumab were more likely to develop
grade3hypertension(10%to12%v0%to2%), and theonlyon-study
death was attributed to uncontrolled hypertension. The overall num-
ber of serious adverse events (Appendix Table A1, online only), de-
fined as any unexpected grade  3 toxicity or toxicity requiring
hospitalization or surgical intervention,was higherwith the investiga-
tional agents, especially bevacizumab; they included febrile neutrope-
nia, infection without neutropenia, nausea/vomiting, diarrhea and
dehydration,bleedingcomplications, thromboembolic events, andGI
perforations. Incidence of immediate (9% v 5%) and delayed (4% v
1%) postoperative complications requiring intervention was also
higher with the addition of bevacizumab.
DISCUSSION
In addition to the trial reported here, two randomized studies have
reported significant increases inpCRrateswith the additionof bevaci-
zumab toNACT inHER2-negative breast cancer.14,15 Both employed
control regimens consisting of an anthracycline-based combination
and docetaxel. However, only in GeparQuinto (fifth German Preop-
erative trial) did adding bevacizumab significantly raise the pCR rate
in 663 patients with TNBC (43% v 33%; two-sided P  .007). In
NSABP(NationalSurgicalAdjuvantBreast andBowelProject)B-40, a
significantly higher pCR rate was reported in hormone receptor–
positive patients, whereas in 320 patients with TNBC, the pCR in-
creasewasnot statistically significant (52% v47%; two-sidedP .34).
In both studies, treatment with bevacizumab was associated with
higher rates of febrile neutropenia, hypertension, mucositis, hand-
foot syndrome, reduced left ventricular function, postoperative
complications, and treatment modifications. The impact of higher
pCR rateswith bevacizumabon long-termoutcomes (RFS andOS)
remains to be seen. However, in two recently reported large ran-
domized trials—BEATRICE (Bevacizumab Adjuvant Therapy in
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Fig 4. Once-per-week paclitaxel (wP) and dose-dense doxorubicin plus cyclophosphamide (ddAC) treatment by delivery arm. Bev, bevacizumab; Carbo, carboplatin.
Table 3. Grade 3 to 4 Treatment-Related Toxicities
Arm One:
Control (%)
Arm Two:
Control 
Bev (%)
Arm Three:
Control 
Carbo (%)
Arm Four:
Control 
Bev and
Carbo (%)
Leukopenia 12 13 13 25
Neutropenia 22 27 56 67
Thrombocytopenia 4 3 20 26
Hemoglobin 0 2 4 5
Febrile neutropenia 7 9 12 24
Nausea 4 4 3 8
Vomiting 2 2 2 4
Mucositis 2 0 1 4
Diarrhea 0 3 2 3
Hypertension 2 12 0 10
ALT elevation 0 3 0 3
Hypokalemia 3 1 6 2
Peripheral neuropathy 2 6 7 4
Fatigue 10 12 10 20
Pain 3 6 3 11
NOTE. Bold font indicates significant difference in incidence compared with
other treatment arms. Early surgical complications requiring intervention 
bevacizumab: 9% versus 5%; delayed surgical complications requiring inter-
vention  bevacizumab: 4% versus 1%.
Abbreviations: Bev, bevacizumab; Carbo, carboplatin.
One treatment-related fatality.
Triple-Negative Breast Cancer; N 2,591, all of whomhadTNBC)
and E5103 (N 4,994, of whom 1,079 had TNBC)—the addition
of bevacizumab to anthracycline- and/or taxane-based adjuvant
chemotherapy failed to improve invasive disease-free survival in
patients with TNBC.16,17 Given these findings, there is scant inter-
est in further investigation of this antiangiogenic agent in early-
stage TNBC.
Three randomized trials have addressed the addition of carbo-
platin toNACT in TNBC, of whichCALGB 40603 is the largest and
the only one to use a control regimen of ddAC and wP.,18,19
GEICAM (Grupo Espan˜ol de Investigacio´n del Ca´ncer de Mama)
2006-03, a much smaller trial (N 94), reported a nonsignificant
drop in pCR (30% v 35%) when carboplatin was added to do-
cetaxel after an anthracycline-based combination.18 In GeparSixto
(sixth German Preoperative trial), 315 patients with TNBC re-
ceived wP 80 mg/m2, nonpegylated liposomal doxorubicin 20
mg/m2 once per week, and bevacizumab 15 mg/kg every 3 weeks,
with or without weekly carboplatin AUC 2, for 18 weeks.19 This
regimen was associated with high rates of grade  3 hematologic
toxicities, especially in patients assigned to carboplatin, and early
treatment discontinuation because of toxicity (control arm, 36%;
carboplatin arm, 49%). Despite these limitations, pCR breast/
axilla (ypT0/isN0) in controls was 43% and increased to 57% with
carboplatin (two-sided P .015).
No TNBC study has compared carboplatin doses and schedules
(AUC 6 every 3 weeks v AUC 2 once per week) concurrently with
single-agentwP,but given results inothermalignancies, theonce-per-
week regimenwould likely cause less severehematologic toxicities and
might be as effective.Although the greater frequencyof skippeddoses,
dose modifications, and early treatment discontinuations with the
addition of carboplatin towP inCALGB40603 andGeparSixto could
raise concern as to whether this might affect the ability of the chemo-
therapy to eradicate occult metastatic disease, thus increasing the risk
ofdistant recurrence, theconsistentassociationofpCRwith improved
RFS and OS in TNBCmakes this unlikely.
A major limitation of available data is the lack of long-term
outcomes, and none of these studies, including CALGB 40603, was
powered to demonstrate statistically significant differences in RFS
or OS. The US Food and Drug Administration–sponsored meta-
analysis of randomized NACT trials confirmed that patients with
TNBC who achieve a pCR have superior event-free survival (haz-
ard ratio, 0.24; 95% CI, 0.18 to 0.33) and OS (hazard ratio, 0.16;
95%CI, 0.11 to 0.25) compared with those who do not.2 However,
even in TNBC, demonstrating that a 13% to 14% absolute increase
in pCR rates (as seen with addition of carboplatin) leads to signif-
icant improvements in long-term outcomes would require a study
many times larger than our trial,20 because some patients will
relapse despite achieving a pCR, whereas many who do not will
remain free of disease. Despite this uncertainty, the US Food and
Drug Administration has affirmed its commitment to considering
applications for accelerated approval for new agents and indica-
tions supported by raising pCR rates in aggressive breast cancer
subtypes like TNBC,21,22 and in 2013, it granted accelerated ap-
proval to neoadjuvant pertuzumab in HER2-positive cancers on
that basis.
TNBC is not a uniform entity.23 By gene expression analysis,
70% to 80% of TNBCs display a basal-like profile, whereas the rest
are a mix of other subtypes.24 Other subclassifications have been
suggested25 and are undergoing clinical validation. BRCA1-
mutation carriers account for 10% to 20%of TNBCs, and although
BRCAmutations are uncommon in sporadic TNBC, dysfunctional
BRCA pathways may also confer platinum sensitivity.26 The avail-
ability of pretreatment tumor samples from patients enrolled onto
CALGB 40603, together with treatment outcome data, provides a
resource for identifying markers of response and resistance, in-
cluding the effects of intrinsic subtype and other proposed classi-
fications and a variety of candidate biomarkers. Ongoing analyses
may lead to the identification of clinically relevant subsets to guide
the design of future TNBC trials, including those studying the role
of platinum analogs, alone or in combination with targeted agents
such as poly (ADP-ribose) polymerase inhibitors.
In summary, higher pCR rates without demonstrated long-term
benefits do not justify the routine addition of bevacizumab in stage II
to III TNBC, especially given associated risks and costs. The addition
of carboplatin to standard NACT for TNBC significantly improves
pCRrates andmay increase thepercentageofpatients eligible forBCS,
but we await evidence that this translates into long-term benefits
before recommending its routine use in clinical practice. Impor-
tant objectives include identifying clinically relevant patient sub-
sets, determining whether carboplatin should be added to existing
regimens or substituted for other agents, and defining its optimal
dose and schedule with regard to efficacy and toxicity. Results from
CALGB 40603 and other studies justify consideration of definitive
trials to determine whether inclusion of carboplatin leads to im-
provements in long-term outcomes in early-stage TNBC, prefera-
bly limited to biologically defined patient subsets believed most
likely to benefit from this treatment.
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GLOSSARY TERMS
antiangiogenic: a process that involves blocking the genera-
tion of new blood vessels in a tumor, which disrupts the blood
supply and thereby prevents tumor growth.
area under the curve (AUC): a measure of the amount of
drug in the blood over a set period of time (eg, 24 hours) that can
be used to determine drug exposure.
bevacizumab: also called Avastin (Genentech, South San
Francisco, CA). Bevacizumab is a recombinant, humanized,
monoclonal antibody that binds and neutralizes the vascular
endothelial growth factor, thus acting as an antiangiogenic
agent.
neoadjuvant therapy: the administration of chemotherapy
prior to surgery. Induction chemotherapy is generally designed to
decrease the size of the tumor prior to resection and to increase
the rate of complete (R0) resections.
pathologic complete response: the absence of any resid-
ual tumor cells in a histologic evaluation of a tumor specimen.
residual cancer burden (RCB): an index to estimate the extent
of residual invasive cancer in the breast and regional lymph nodes after
neoadjuvant chemotherapy. RCB combines parameters derived from
the review of routine pathology materials: two-dimensional extent of
residual primary tumor, proportion of this primary tumor area that
contains cancer cells, proportion of the residual primary cancer that is
in situ, the number of involved regional lymph nodes, and the diameter
of the largest nodal metastasis.
sentinel lymph node: the lymph node that is anatomically located
such that it is the first site of lymph drainage from the location of the
primary tumor. It is suspected and assumed that if a malignancy is going
to disseminate via the lymphatic system, metastases will first be evident
in the sentinel lymph node. In this manner, this lymph node is said to
stand guard or sentinel over the metastatic state of the tumor. For many
cancers, the sentinel lymph node is biopsied as part of the staging pro-
cess and presence of macro- or micrometastases in the sentinel lymph
node is a negative prognostic factor.
triple-negative phenotype: breast tumors that are negative for
progesterone and estrogen and that underexpress HER2.
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Table A1. No. of Patients With Serious AEs
AE Arm One: Control Arm Two: Control  Bev Arm Three: Control  Carbo Arm Four: Control  Bev and Carbo
Total 15 39 29 46
Febrile neutropenia 5 15 10 17
Infection without neutropenia 4 10 2 9
Nausea/vomiting/dehydration 1 5 5 6
Bleeding 0 2 0 5
Thromboembolic events 1 6 1 4
GI perforation 0 1 0 1
NOTE. Bold font indicates significant difference in incidence compared with other treatment arms.
Abbreviations: AE, adverse event; Bev, bevacizumab; Carbo, carboplatin.
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